



## **Metabolix Announces that Mirel Bioplastics is Chosen by Labcon for New Laboratory Liquid Handling System**

**CAMBRIDGE, Mass., June 30, 2008** – Metabolix Inc. (NASDAQ: MBLX) today announced that Telles™, its joint venture with Archer Daniels Midland Company that produces Mirel™ bioplastics, has entered into an agreement to supply Mirel bioplastic resin to Labcon North America, a leading manufacturer of laboratory supplies, for the production of its new Pagoda pipet reloading system.

“Labcon’s product launch demonstrates business equipment as one of our strategic short term applications for which Mirel will be utilized,” said Bob Findlen, Vice President of Sales and Marketing, Telles. “This very complicated part demonstrates the versatility and ease with which Mirel can be used for injection molding applications. Until today, bioplastics in general have had limited capability in injection molding applications.”

Labcon North America is a leading provider of disposable plastic laboratory products, supplying more than 800 products globally, and manufacturing over a billion units a year. The new Labcon Pagoda reloading system utilizes Mirel for the injection molded tray that holds the pipets in place. Mirel is biobased and biodegradable, which means the product tray, can now be composted at the end of its useful life.

Jim Happ, President of Labcon said: “There has been growing concern within our industry that the disposal of traditional plastics is too wasteful. We can now offer customers the opportunity to lower their carbon footprint with our Pagoda line of products and many have indicated that they will switch to our new products made from renewable resources. We envision this as the first of many products in our Pagoda line that will utilize Mirel.”

“Labcon previously supplied conventional plastic trays that were thrown away or reclaimed through Labcon’s recycle program. Now we are planning to launch a composting program to complement this initiative,” said Happ.

“Labcon selected Mirel for its improved physical properties, heat and chemical resistance, durability, and dimensional stability”, said Tom Moulton, director of marketing of Labcon. “These physical properties are essential features for Labcon applications.”

### **About Metabolix**

Founded in 1992, Metabolix, Inc. is an innovation driven bioscience company focused on providing sustainable solutions for the world’s needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel™ bioplastics, a sustainable and biodegradable alternative to petroleum-based plastics. Mirel is suitable for injection molding, extrusion coating, cast film and sheet, blown film and thermoforming. Metabolix is also developing a proprietary platform technology for

co-producing plastics, chemicals and energy, from crops such as switchgrass, oilseeds and sugarcane.

Metabolix and Archer Daniels Midland Company (ADM) are commercializing Mirel through a joint venture called Telles. The first commercial scale Mirel production plant is being constructed adjacent to ADM's wet corn mill in Clinton, Iowa. The plant is designed to produce up to 110 million pounds of Mirel annually. Mirel will reduce reliance on petroleum and decrease environmental impacts relative to conventional petroleum-based plastics.

For more information, please visit [www.metabolix.com](http://www.metabolix.com). (MBLX-G)

#### **About Labcon North America**

Labcon North America is a leading manufacturer of disposable laboratory products for research, pharmaceutical, and biotechnology laboratories throughout the world. Since 1995 Labcon North America has focused on the development and marketing of disposables that incorporate the principles of sustainability and eco-efficiency.

For more information please visit [www.labcon.com](http://www.labcon.com)

#### ***Safe Harbor for Forward-Looking Statements***

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expected waste disposal trends, projected market size, future demand for Mirel™, the capacity of the Mirel commercial manufacturing facility, commercial viability of Mirel, and management's strategy, plans and objectives for future operations, product development, and research and development, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: uncertainties related to potential future market demand, the Company's dependence on ADM for construction of the commercial manufacturing facility, ADM's ability to complete construction of that facility on time and on budget, the ability of Metabolix and ADM to successfully manufacture Mirel at commercial scale and in a timely and economic manner, the Company's ability to develop Mirel products, uncertainties regarding market acceptance of Metabolix products, dependence on Metabolix's customers for commercialization of Mirel products, the Company's ability to compete with petroleum-based plastics and with other biobased products, the success of Metabolix research and development programs, and other risks detailed in Metabolix's filings with the Securities and Exchange Commission, including form 10-K for the year ended December 31, 2007. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

#### **Contacts**

**Media:**

Matt Lindberg, ICR, (203) 682-8214, [matthew.lindberg@icrinc.com](mailto:matthew.lindberg@icrinc.com)

Brian Ruby, ICR, (203) 682-8268, [brian.ruby@icrinc.com](mailto:brian.ruby@icrinc.com)

**Investors:**

Kathleen Heaney, ICR, (203) 803-3585, [kheaney@icrinc.com](mailto:kheaney@icrinc.com)